Session 0880 – Plenary 01: Opening, Presentation of Award and Late Breaking Trials (ID 294) Early rhythm-control therapy for atrial fibrillation in patients with history of stroke in the EAST-AFNET4 trial
Wednesday, 26th of October 2022 | / 12:10 – 12:20 pm (CEST)/ 18:10 – 18:20 pm (SGT), room “Hall 406”
Speaker: Märit Jensen
The NOAH – AFNET 6 trial which is conducted to evaluate the potential benefit of oral anticoagulation in patients with atrial high rate episodes (AHRE) is going to be terminated prematurely. The reason for early termination is an observed trend towards futility for efficacy combined with expected safety concerns. Following a recommendation of the study scientific committees, on 2 September 2022, AFNET decided to orderly terminate the NOAH – AFNET6 trial in the coming weeks. The study results will be available next year.
The study “CABA-HFPEF-DZHK27” (CAtheter-Based Ablation of atrial fibrillation vs. conventional treatment in patients with Heart Failure with Preserved Ejection Fraction) is aiming for a better therapy for patients with heart failure and atrial fibrillation. Charité (Berlin, Germany) has the overall responsibility for the study. This trial is supported by German Centre for Cardiovascular Research (DZHK). Further information can be found in the press release (german only).
A mediator analysis of the EAST – AFNET 4 trial dataset revealed the key factor for the effectiveness of early rhythm control (ERC) in patients with atrial fibrillation (AF): The presence of sinus rhythm at 12 months after randomization explains 81% of the outcome-reducing effect of ERC. Other factors, e. g. blood pressure or recurrent AF, only explain small portions of the effect. The results were presented by Professor Lars Eckardt, University Hospital Münster, Germany, at the annual congress of the European Society of Cardiology (ESC) in Barcelona, Spain, on 29.08.2022 [1], [2].
The 8th AFNET/EHRA Consensus Conference Paper 2021 “Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation” has been published:
The current issue of “theme booklet of neurology” reports on Atrial Fibrillation NETwork (AFNET), get your access here (german only).
The newest subanalysis of the EAST-AFNET 4 study will be presented at this year’s ESC congress 2022 in Barcelona:
Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control
The design paper was successfully published in “Frontiers in cardiovascular medicine”. Get access to the paper here.
The latest results of the EAST-AFNET 4 study will be presented at this year’s EHRA congress 2022:
Late Breaking Clinical Trials II
Atrial fibrillation – News on ablation and sex differences
Monday, 4th of April 2022 | 6:15 pm – 7:15 pm (CEST), Room 1
Session chaired by Tatjana Potpara
More information
